Activation of the Aryl-Hydrocarbon Receptor Inhibits Invasive and Metastatic Features of Human Breast Cancer Cells and Promotes Breast Cancer Cell Differentiation
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The current statistics associated with breast cancer continue to show a relatively high recurrence rate together with a poor survival for aggressive metastatic disease. These findings reflect, in part, the pharmaceutical intractability of processes involved in the metastatic process and highlight the need to identify additional drug targets for the treatment of late-stage disease. In the current study, we report that ligand activation of the aryl-hydrocarbon receptor (AhR) inhibits multiple aspects of the metastatic process in a panel of breast cancer cell lines that represent the major breast cancer subtypes. Specifically, it was observed that treatment with exogenous AhR agonists significantly inhibited cell invasiveness and motility in the Boyden chamber assay and inhibited colony formation in soft agar regardless of estrogen receptor (ER), progesterone receptor, or human epidermal growth factor receptor 2 status. Knockdown of the AhR using small interfering RNA duplexes demonstrated that the inhibition of invasiveness was receptor dependent and that endogenous receptor activity was protective in each cell type examined. The inhibition of invasiveness and anchorage-independent growth correlated with the ability of exogenous AhR agonists to promote differentiation. Finally, exogenous AhR agonists were able to promote differentiation in a putative mammary cancer stem cell line. Cumulatively, these results suggest that the AhR plays an important role in mammary epithelial differentiation and, as such, represent a promising therapeutic target for a range of phenotypically distinct human breast cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“Certain cancer therapies function by inducing cell cycle arrest, blocking replication, and promoting differentiation of cancer cells into cells resembling their tissue of origin (40, 41).”
BackgroundPoland, A., & Knutson, J. C. (1982) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.22.040182.002505 · Cited by 2,515
Immune System Impairment and Hepatic Fibrosis in Mice Lacking the Dioxin-Binding Ah Receptor
Fernandez-Salguero, P., Pineau, T., Hilbert, D. M., McPhail, T., Lee, S. S. T., Kimura, S., Nebert, D. W., Rudikoff, S., Ward, J. M., & Gonzalez, F. J. (1995) · Science · doi:10.1126/science.7732381 · Cited by 1,075
Rules for Making Human Tumor Cells
Hahn, W. C., & Weinberg, R. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra021902 · Cited by 951 · cited 1×
“conserved (8) and plays a significant role in tissue devel-”
BackgroundAryl hydrocarbon receptors: diversity and evolution
Hahn, M. E. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00070-4 · Cited by 642
Lahvis, G. P., Lindell, S. L., Thomas, R. S., McCuskey, R. S., Murphy, C., Glover, E., Bentz, M., Southard, J., & Bradfield, C. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.190256997 · Cited by 377
Self-citationCloning and expression of a human Ah receptor cDNA.
Dolwick, K. M., Schmidt, J. V., Carver, L. A., Swanson, H. I., & Bradfield, C. A. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13282-3 · Cited by 348
Intrinsic Function of the Aryl Hydrocarbon (Dioxin) Receptor as a Key Factor in Female Reproduction
Baba, T., Mimura, J., Nakamura, N., Harada, N., Yamamoto, M., Morohashi, K.-I., & Fujii-Kuriyama, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10040-10051.2005 · Cited by 256 · cited 1×
“(14), ovarian follicle development (15), seminal vesicle”
Cited by
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Cheong, J. E., & Sun, L. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.007 · Cited by 487
CH223191 Is a Ligand-Selective Antagonist of the Ah (Dioxin) Receptor
Zhao, B., DeGroot, D. E., Hayashi, A., He, G., & Denison, M. S. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq217 · Cited by 312
Role of the Aryl Hydrocarbon Receptor in Carcinogenesis and Potential as a Drug Target
Safe, S., Lee, S.-O., & Jin, U.-H. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft128 · Cited by 264
Novikov, O., Wang, Z., Stanford, E. A., Parks, A. J., Ramirez-Cardenas, A., Landesman, E., Laklouk, I., Sarita-Reyes, C., Gusenleitner, D., Li, A., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105361 · Cited by 167
“Paradoxically, AHR hyperactivation with exogenous ligands may also lead to reduced breast cancer cell invasion (Hall et al., 2010; Prud ’ homme et al., 2010; Zhao et al., 2012; Safe et al., 2013; Jin et al., 2014), suggesting that endogenous and exogenous ligands may induce different signaling…”
BackgroundAHR Ligands: Promiscuity in Binding and Diversity in Response
DeGroot, D., He, G., Fraccalvieri, D., Bonati, L., Pandini, A., & Denison, M. S. (2011) · The AH Receptor in Biology and Toxicology · doi:10.1002/9781118140574.ch4 · Cited by 43
Metadata
- Authors
- Hall, J. M., Barhoover, M. A., Kazmin, D., McDonnell, D. P., Greenlee, W. F., & Thomas, R. S.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2010-02
- Volume
- 24
- Issue
- 2
- Pages
- 359-369
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2076927594
- Cited by
- 112
- References
- 8
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activation of the Aryl-Hydrocarbon Receptor Inhibits Invasive and Metastatic Features of Human Breast Cancer Cells and Promotes Breast Cancer Cell Differentiation. https://app.cochat.ai/papers/10.1210/me.2009-0346
- The paper
- Hall, J. M., Barhoover, M. A., Kazmin, D., McDonnell, D. P., Greenlee, W. F., & Thomas, R. S. (2010). Activation of the Aryl-Hydrocarbon Receptor Inhibits Invasive and Metastatic Features of Human Breast Cancer Cells and Promotes Breast Cancer Cell Differentiation. Molecular Endocrinology. https://doi.org/10.1210/me.2009-0346
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.